^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Progesterone receptor agonist

    Related drugs:
    1d
    HMB-BD: Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Oregon Health and Science University | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    MATRIX: Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC (clinicaltrials.gov)
    P3, N=60, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting --> Recruiting | Initiation date: Jun 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    |
    oxaliplatin • megestrol
    7d
    Is age just a number? Oncotype DX testing and chemotherapy use in the post-TAILORx era. (PubMed, Cancer)
    In the post-TAILORx era, younger age was associated with substantially more ODX testing. The association of testing with chemotherapy varied substantially by age. The impact of age on ODX testing and use of chemotherapy is substantial and warrants further study.
    Journal
    |
    Oncotype DX Breast Recurrence Score®Test
    7d
    Delayed onset of HPV-associated uterine malignancies: seven pathogenetic factors in contrast to cervical cancer. (PubMed, Rom J Morphol Embryol)
    Hormonal factors, especially prolonged unopposed estrogen exposure and progesterone-driven immune tolerance, modulate both tissue susceptibility and viral persistence...We also discuss emerging data suggesting that endometriosis and other ectopic endometrial proliferations may act as viral reservoirs. Overall, HPV appears to function as a co-factor within a multifactorial pathogenetic network, contributing to a subset of endometrial malignancies after a protracted, decades-long carcinogenic course.
    Review • Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • MME (Membrane Metalloendopeptidase)
    7d
    MRI-PCOS: Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov)
    P=N/A, N=52, Completed, University Hospital, Lille | Active, not recruiting --> Completed
    Trial completion
    |
    cyproterone acetate
    7d
    Intrauterine Stent Placement Following Hysteroscopic Septum Resection (clinicaltrials.gov)
    P=N/A, N=320, Not yet recruiting, Weill Medical College of Cornell University | Initiation date: Oct 2025 --> Jan 2026 | Trial primary completion date: Jan 2028 --> Sep 2029
    Trial initiation date • Trial primary completion date
    |
    medroxyprogesterone
    7d
    Ruhe Sanjie Tablet ameliorates depression-associated mammary gland hyperplasia by modulating estrogen receptor signaling and CDK2. (PubMed, J Ethnopharmacol)
    RST alleviates MGH and its comorbid depressive behaviors through multi-target actions involving hormonal rebalancing, suppression of estrogen receptor signaling, inhibition of CDK2-mediated cell cycle progression, and modulation of inflammatory metabolites.
    Journal
    |
    ER (Estrogen receptor) • CCNE1 (Cyclin E1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CDK2 (Cyclin-dependent kinase 2) • PCNA (Proliferating cell nuclear antigen) • IL1B (Interleukin 1, beta)
    8d
    Observation of the Response to Ovulation Triggering on the Day of Intrauterine Insemination and Correlation Between Progesterone Level and Pregnancy Rate (OVUL-IIU) (clinicaltrials.gov)
    P=N/A, N=158, Completed, Centre Hospitalier Intercommunal Creteil | Recruiting --> Completed
    Trial completion
    10d
    SUNFLOWER: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months (clinicaltrials.gov)
    P3, N=207, Recruiting, Bayer | Not yet recruiting --> Recruiting | Trial completion date: Jan 2027 --> May 2027 | Trial primary completion date: Jan 2027 --> May 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    medroxyprogesterone
    10d
    An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (clinicaltrials.gov)
    P1, N=24, Recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
    New P1 trial
    11d
    Partial Progesterone Deprivation Affects the Expression of Apoptosis-Specific Genes and Proteins in a Zone-Specific Manner in Rat Placenta. (PubMed, Cureus)
    Conclusion The modulatory effect of progesterone did not result in improved fetal body weight, likely due to the variable impact of progesterone on the expression of pro- and anti-apoptotic proteins within the labyrinth and basal zones across different gestational days. Implication: These findings indicate that the effect of progesterone on cell death and survival pathways is zone-specific, reflecting different regulatory mechanisms within different placental regions.
    Preclinical • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    13d
    The Role of Hormones in Postpartum Mood Disorders (clinicaltrials.gov)
    P2, N=74, Completed, National Institute of Mental Health (NIMH) | N=54 --> 74
    Enrollment change
    |
    leuprolide acetate for depot suspension